A pharmaceutical composition comprising a sodium-dependent glucose transporter (SGLT2) inhibitor and a biguanide, wherein at least one of the active agents is in slow release form, is provided. A method for treating diabetes in a patient in need thereof including administering an anti-diabetic combination comprising a sodium-dependent glucose transporter (SGLT2) inhibitor and a biguanide, wherein at least one of the active agents is in slow release form, is also provided.
